Sponsor or institution
Clinical trials and research at Nanjing IASO Biotechnology Co., Ltd.
As of November 12, 2026, Find a Trial lists 6 clinical trials run by Nanjing IASO Biotechnology Co., Ltd. that are recruiting, in China. By phase: Phase 1 (5). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| IASO-782 for Systemic Lupus Erythematosus | Phase 1 | Hangzhou, Zhejiang and 3 other locations | Recruiting | Mar 19, 2026 |
| UB-VV410 for adults with active, treatment-refractory systemic lupus and lupus nephritis | Phase 1 | Nanjing | Recruiting | Aug 7, 2025 |
| Long-term follow-up of Eque-cel (Equecabtagene Autoleucel) for multiple myeloma | — | Beijing and 5 other locations | Recruiting | Jun 19, 2025 |
| UB-VV400 plus rapamycin for relapsed or refractory large B‑cell lymphoma | Phase 1 | Nanjing and 1 other locations | Recruiting | Dec 20, 2024 |
| IASO-782: a first-in-human test for autoimmune ITP and wAIHA | Phase 1 | Wuhan, Hubei and 1 other locations | Recruiting | Aug 1, 2024 |
| CAR-GPRC5D treatment for patients with relapsed or refractory multiple myeloma or plasma cell leukemia | Phase 1 | Shanghai | Recruiting | Mar 8, 2023 |
All recruiting trials (6)
-
IASO-782 for Systemic Lupus Erythematosus
A small, early-stage trial tests whether IASO-782 is safe and tolerable for adults with SLE, using a randomized, placebo-controlled design.
-
UB-VV410 for adults with active, treatment-refractory systemic lupus and lupus nephritis
This trial will test whether UB-VV410 is safe and how it acts in adults with active, treatment-refractory systemic lupus erythematosus, including those with lupus nephritis.
-
Long-term follow-up of Eque-cel (Equecabtagene Autoleucel) for multiple myeloma
This follow-up will see how people with multiple myeloma who previously received Eque-cel (Equecabtagene Autoleucel) are doing over time.
-
UB-VV400 plus rapamycin for relapsed or refractory large B‑cell lymphoma
This will test UB‑VV400 alone and together with rapamycin to see if it's safe and helps adults with relapsed or refractory large B‑cell lymphoma, including people who have had CAR‑T therapy.
-
IASO-782: a first-in-human test for autoimmune ITP and wAIHA
This phase 1b-ready study will test whether IASO-782 is safe and tolerable in adults with autoimmune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) who have not fully responded to prior treatments.
-
CAR-GPRC5D treatment for patients with relapsed or refractory multiple myeloma or plasma cell leukemia
This study is testing a new CAR-T cell treatment called CAR-GPRC5D to see if it can help people with relapsed or hard-to-treat multiple myeloma or plasma cell leukemia.
Quick answers
How many clinical trials run by Nanjing IASO Biotechnology Co., Ltd. are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 5. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.